FCH
BCRX icon

Freestone Capital Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

Freestone Capital Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,000
Closed -$277K – 585
2021
Q4 		$277K Buy
+20,000
New +$265K 0.01% 423
2021
Q1 		– Sell
-2,000
Closed -$14.9K – 460
2020
Q4 		$14.9K Hold
2,000
– – ﹤0.01% 776
2020
Q3 		$6.87K Buy
+2,000
New +$8.57K ﹤0.01% 815

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Capital Holdings's BCRX Position: Q1 2022 in Review

Freestone Capital Holdings sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2022, closing a stake of 20,000 shares — an estimated $277K sold.

Freestone Capital Holdings first reported a position in BCRX in Q3 2020 and held it in 3 quarters. The position peaked at $277K in Q4 2021. 233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

  • Freestone Capital Holdings reported no remaining BioCryst Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Freestone Capital Holdings sold 20,000 BioCryst Pharmaceuticals shares in Q1 2022, an estimated $277K.
  • Freestone Capital Holdings first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Freestone Capital Holdings's BioCryst Pharmaceuticals position peaked at $277K in Q4 2021.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on Freestone Capital Holdings's 13F filing for Q1 2022, filed 12 May 2022.